Hints and tips:
Related Special Reports
...Haymarket also lent $91mn to Jarm Capital, a Delaware company then owned by Josh Wander, co-founder of 777, according to a person familiar with the situation....
...Three years ago, the outlook seemed grim for the UK’s financial mutuals and co-operatives — organisations owned by their customers....
...The drugs used to treat ADHD, usually stimulants such as amphetamines, are highly effective, according to Smith, making diagnosis and treatment an “economically smart” investment....
...Along with striking a co-brand deal with CVS to offer Hyrimoz at a discounted price of $1,315 a month, Sandoz has a higher list price version of the biosimilar, priced similarly to Humira at more than $6,000...
...Security co-operation between Mexico and the US, which share a 2,000-mile border, involves a web of agencies....
...Bobby Gaspar, co-founder and chief executive of Orchard, said Lenmeldy was “a paradigm-shifting medicine”, adding that the company was “committed to enabling broad, expedient and sustainable access to this...
...Leqembi, priced at $26,500 a year, was the first drug with a black-box warning — the most severe designation about possible side effects — to be granted full approval by the US Food and Drug Administration...
...Mondi’s offer valued DS Smith at roughly £6.2bn, including debt....
...European defence: MBDA, a pan-European weapons maker that successfully overcame national interests to compete with US rivals, is being held up as a model of defence co-operation needed in the region....
...China has warned the US that Washington and Beijing must choose between “confrontation or co-operation” as secretary of state Antony Blinken began an official visit during which he is expected to deliver...
...International Paper’s all-share proposition for DS Smith is equivalent to 415p per share, which would value the company at roughly £6.8bn including debt....
...Huge demand for GLP-1s, the lucrative new class of diabetes and weight-loss drugs that include Wegovy and Zepbound, is testing the capacity of plants capable of producing and administering the drug. 4....
...Scientists have hailed an important advance in the decades-old quest for a drug to slow the impact of Parkinson’s disease....
...“What we’re trying to do is give the liver a little nudge in the right direction to support it to regenerate,” said Quin Wills, chief scientific officer and co-founder of Ochre Bio....
...Eli Lilly’s tirzepatide drug had less than 10 per cent absolute weight reduction at all doses after its late-stage trial, noted Thomas Smith, an analyst at Leerink Partners....
...The US drug regulator has delayed an approval decision on Eli Lilly’s promising Alzheimer’s disease drug, which was expected to be greenlit this month....
...Jessica SmithI’m Jessica Smith, in for Marc Filippino, and here’s the news you need to start your day....
...The company said the decision was partly driven by huge demand for weight-loss drugs....
...drugs....
...“It’s not beyond the realms of possibility that [underwriters] could process 10 times the volume,” said David King, co-founder and co-chief executive of Artificial Labs, which offers fully automated underwriting...
...insurers to cover the drug....
...Here are more details about the co-founder’s plans. 5....
...Chart of the day When Andrés Manuel López Obrador took office in 2018, agents at the US Drug Enforcement Administration knew their job was about to become a lot more difficult....
...The comments indicate a rare moment of co-operation at a time of trade tensions between the two powers. Read the full interview....
...Zealand’s earlier drug candidates include a non-GLP-1 drug for obesity based on amylin that Steensberg said could reduce side effects such as nausea....
International Edition